Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Portola Pharmaceuticals Inc. (PTLA)

NEW YORK, NY / ACCESSWIRE / January 20, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Portola Pharmaceuticals Inc. ("Portola" or the Company") (NASDAQ:PTLA).Investors who purchased Portola securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ptla.

The investigation concerns whether Portola and certain of its officers and/or directors have violated federal securities laws.

On January 9, 2020, Portola announced preliminary net revenues of only $28 million for the fourth quarter of 2019. Portola attributed the result to a $5 million reserve adjustment for short-dated product, and flat quarter-over-quarter demand. On this news, Portola's stock price fell $9.98 per share, or 40.34%, to close at $14.76 per share on January 10, 2020.

If you are aware of any facts relating to this investigation, or purchased Portola shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/ptla. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 573573